0001104659-23-125566.txt : 20231213 0001104659-23-125566.hdr.sgml : 20231213 20231213070808 ACCESSION NUMBER: 0001104659-23-125566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231213 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 231482959 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 8-K 1 tm2332757d1_8k.htm FORM 8-K

The UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 13, 2023

BLACK DIAMOND THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39200	81-4254660
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

One Main Street, 14^th Floor
Cambridge, Massachusetts		02141
(Address of Principal Executive Offices)		(Zip Code)

(617) 252-0848

(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	BDTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01.

Regulation FD Disclosure.

On December 13, 2023, Black Diamond Therapeutics, Inc. (the “Company”) issued a press release titled “Black Diamond Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM.” A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01.

Other Events.

On December 13, 2023, the Company announced topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535 in patients with recurrent glioblastoma (“GBM”) who expressed epidermal growth factor receptor (“EGFR”) alterations at the time of their initial diagnosis.

Phase 1 Dose Escalation Clinical Trial Topline Results in Patients with Recurrent GBM

Clinical data as of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15 mg to 400 mg once daily (“QD”) in the dose escalation cohort. No new safety signals were observed, and adverse events were consistent with the EGFR tyrosine kinase inhibitor class of drugs, including primarily Grade 1 and 2 diarrhea and rash. Patients with non-small cell lung cancer dosed at 100 mg QD or greater demonstrated confirmed partial responses in lung lesions and central nervous system metastases.

Key enrollment and inclusion factors:

	·	Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100 mg QD or greater and reached at least one post baseline tumor assessment.
	·	Patients were heavily pretreated, with a median of two prior lines of therapy (range of one to four). All patients except one had received prior temozolomide. Other prior treatments included chemotherapy, bevacizumab, checkpoint inhibitors or investigational agents.
	·	Patients were required to have EGFR alterations at the time of diagnosis, but EGFR status was not known at time of treatment with BDTX-1535 as biopsies are not commonly performed for recurrent disease.

Key results:

	·	Of the 22 patients evaluable for efficacy, three patients were on therapy longer than ten months, one patient longer than six months, and five patients longer than four months. Historical progression-free survival in this population is in the range of two to four months.
	·	The patient on therapy the longest remains on BDTX-1535 at 100 mg QD for over fifteen months with prolonged disease stabilization. This patient had previously progressed after three months of temozolomide treatment.
	·	Of the 19 patients with measurable disease by Response Assessment in Neuro-Oncology criteria, one patient achieved a confirmed partial response and eight patients experienced stable disease. The patient with the confirmed partial response stayed on treatment for longer than four months at 200 mg QD.

The Company plans to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024.

Forward-Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward looking statements. Such statements include, but are not limited to, the continued development and advancement of BDTX-1535, including the Phase 1 clinical trial and the expected timing for presentation of the full BDTX-1535 dose escalation data in GBM, and the potential of BDTX-1535 to benefit patients with GBM in an earlier line of treatment. In some cases, you can identify forward-looking statements by terminology such as “believe,” “estimate,” “intend,” “may,” “plan,” “potentially,” “will,” “expect,” “enable,” “likely” or the negative of these terms or other similar expressions. Any forward-looking statements in this Current Report on Form 8-K are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the United States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Black Diamond Therapeutics, Inc., dated December 13, 2023.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BLACK DIAMOND THERAPEUTICS, INC.


Date: December 13, 2023	By:	/s/ Brent Hatzis-Schoch
	Name:	Brent Hatzis-Schoch
	Title:	Chief Operating Officer and General Counsel

EX-99.1 2 tm2332757d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Initial results show promising clinical activity in heavily pretreated patients

22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months

19 patients with measurable disease by RANO criteria: 1 patient with confirmed partial response and 8 patients with stable disease

BDTX-1535 generally well tolerated, consistent with prior disclosures and no new safety signals observed

“Window of opportunity” trial enrolling patients to assess PK in brain tissue

CAMBRIDGE, Mass., December 13, 2023 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced topline results from the dose escalation portion of the Phase 1 clinical trial of BDTX-1535 in patients with recurrent glioblastoma (GBM) who expressed epidermal growth factor receptor (EGFR) alterations at the time of their initial diagnosis. BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or GBM.

“These initial results in patients with recurrent GBM are encouraging, as there are no approved therapies available for those who progress following initial treatment, and there is strong rationale for a brain penetrant, covalent EGFR inhibitor such as BDTX-1535 to have a meaningful impact in earlier lines of therapy,” said Patrick Wen, M.D., Director of The Center for Neuro-Oncology at Dana-Farber Cancer Institute.

Clinical data as of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15mg to 400mg once daily (QD) in the dose escalation cohort. Combined pharmacokinetic (PK) and safety data from these 27 patients with GBM and 27 patients with NSCLC were previously presented on October 14, 2023 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. No new safety signals were observed; adverse events were consistent with the EGFR tyrosine kinase inhibitor (TKIs) class of drugs, including primarily Grade 1 and 2 diarrhea and rash. Patients with NSCLC dosed at 100mg QD or greater demonstrated confirmed partial responses in lung lesions and CNS metastases.

Key enrollment and inclusion factors

	·	Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100mg QD or greater and reached at least one post baseline tumor assessment.
	·	Patients were heavily pretreated, with a median of 2 prior lines of therapy (range 1-4). All patients except one had received prior temozolomide. Other prior treatments included chemotherapy, bevacizumab, checkpoint inhibitors or investigational agents.
	·	Patients were required to have EGFR alterations at the time of diagnosis, but EGFR status was not known at time of treatment with BDTX-1535 as biopsies are not commonly performed for recurrent disease.

Key results

	·	Of the 22 patients evaluable for efficacy, 3 patients were on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months. Historical progression-free survival (PFS) in this population is in the range of 2-4 months.
	·	The patient on therapy the longest remains on BDTX-1535 at 100mg QD for over 15 months with prolonged disease stabilization. This patient had previously progressed after 3 months of temozolomide treatment.
	·	Of the 19 patients with measurable disease by Response Assessment in Neuro-Oncology (RANO) criteria, 1 patient achieved a confirmed partial response (PR) and 8 patients experienced stable disease (SD). The patient with the PR stayed on treatment for longer than 4 months at 200 mg QD.

Black Diamond plans to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024. Enrollment is ongoing in a “window of opportunity” clinical trial of BDTX-1535 in second-line patients with high-grade glioma. The trial (NCT06072586) is sponsored by the Ivy Brain Tumor Center in Phoenix, Arizona and is enrolling patients prior to a planned resection in order to assess PK and pharmacodynamics (PD) in brain tissue. Patients achieving adequate drug levels in the gadolinium non-enhancing regions of the tumor will continue with treatment following surgery. The trial will enroll up to 22 patients, and clinical data is expected in the second quarter of 2024.

“We believe the ‘window of opportunity’ trial of BDTX-1535 will provide valuable information on both drug levels in the brain and clinical activity in second-line patients, and will inform potential next steps in our development program,” said Sergey Yurasov, M.D., Ph.D., Chief Medical Officer of Black Diamond Therapeutics. “More than half of all newly diagnosed GBM patients express an altered form of EGFR, and preclinical data demonstrate BDTX-1535 potently inhibits this spectrum of alterations. Therefore, BDTX-1535 may be optimally suited to benefit first-line patients.”

About BDTX-1535

BDTX-1535 is an oral, brain-penetrant MasterKey inhibitor of oncogenic epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC), including families of non-classical driver mutations (e.g., L747P, L718Q), acquired resistance C797S mutation, and complex mutations. BDTX-1535 is a fourth generation TKI that potently inhibits, based on preclinical data, more than 50 oncogenic EGFR mutations expressed across a diverse group of patients with NSCLC in multiple lines of therapy. Based on preclinical data, BDTX-1535 also inhibits EGFR extracellular domain mutations and alterations commonly expressed in glioblastoma (GBM) and avoids paradoxical activation observed with earlier generation reversible TKIs. Dose escalation of BDTX-1535 in patients with GBM is complete and dose expansion is currently ongoing in patients with NSCLC (NCT05256290).

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat CNS disease. The Company is advancing two clinical stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the continued development and advancement of BDTX-1535, including the Phase 1 clinical trial, the expected timing for clinical updates on data from the “window of opportunity” clinical trial of BDTX-1535 in recurrent GBM patients and presentation of the full BDTX-1535 dose escalation data in GBM, and the potential of BDTX-1535 to benefit patients with GBM in an earlier line of treatment. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the United States Securities and Exchange Commission and in its subsequent filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts

For Investors:

Mario Corso, Head of Investor Relations, Black Diamond Therapeutics

mcorso@bdtx.com

For Media:

media@bdtx.com

EX-101.SCH 3 bdtx-20231213.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bdtx-20231213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bdtx-20231213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2332757d1_ex99-1img001.jpg GRAPHIC begin 644 tm2332757d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 13, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 13, 2023
Entity File Number	001-39200
Entity Registrant Name	BLACK DIAMOND THERAPEUTICS, INC.
Entity Central Index Key	0001701541
Entity Tax Identification Number	81-4254660
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	One Main Street, 14th Floor
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02141
City Area Code	617
Local Phone Number	252-0848
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	BDTX
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false

XML 8 tm2332757d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001701541 2023-12-13 2023-12-13 iso4217:USD shares iso4217:USD shares false 0001701541 8-K 2023-12-13 BLACK DIAMOND THERAPEUTICS, INC. DE 001-39200 81-4254660 One Main Street, 14th Floor Cambridge MA 02141 617 252-0848 false false false false Common Stock, $0.0001 par value per share BDTX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,YC5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #.8U748ULK^T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OITE!)'1S6?&D(+B@> O)[&ZP:4,RTN[;F\;=+J(/X#$S?[[Y M!J8S09HQXG,< T9RF&YFWP])FK!A1Z(@ 9(YHM>ISHDA-_=C])KR,QX@:/.A M#PBB:6[!(VFK2<,"K,)*9*JS1IJ(FL9XQENSXL-G[ O,&L >/0Z4@-<U*+-4_L:4#[)R0<.;T^/+V7=R@V) M]& P_TI.TBG@AETFO[;;^]T#4Z(1;<5%Q=L=%[*YDTW[OKC^\+L*^]&ZO?O' MQA=!U<&ONU!?4$L#!!0 ( ,YC5>97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M SF-5U;"9H2,! 0Q$ !@ !X;"]W;W)K=(<$R#R$I,$. ])@DA NDUVFG+X0M0!/;\DER2+Y] M5P9L[LZLR8M@&>_?/^VN=B6Z6ZE>]89S0]ZC,-8]9V-,Z/>[R9LS>?TW%(P%]\[XLB@Z9TP\/8&7L:]>U%&.6*&];M*;HFR3X.:O"',/+,;Q,KX%AD'\'2VT4!.J_,J*=0K-P2BF4,T494!$ 09Q5W(UF44 MN/V*A9HC'*V,V9<"1F0<1P02+Y2OU0H'=*H*H_:.5H;%1S'1I@/E%XQK*&L)SE?-X36#]-5T(%JA#;-!JJ3E K#+KH"18OZ#]A#.P*G M+N0V+D7&Y88L6BH1K+$B2(N60/&B_CU<'O*9DF\B]LN=BFL^#C"THE%0O-)_ MCS:3VL":_D1L$%VO0* RE:!<7K_(/T MP2>SC8RQ7E$AXK6\"[?3[&!$1;.@>)7_HH0Q/ ;'1%$:[^N<+J7"A:HZ/2V: M L5K^5R&PA=&Q&M8Z ;Z/0M+>7"52IZB&U"\>,\4O_#!/1S6UVY#!GLBV#H^ MK58GXH?K59%Y11_P\$K] ]E$ZQ3(J@ K9"L!BQ[@X05[(0SLBN2*4.^WY>]D MSOT4\JVTOU#SQA3 M4>J]LTK]..)J;;WT)RA #X80)2PN#RXN:%2*QJTH]!Y>I\?VY,T#,I6P2B5Y MT9R8#0??&;LB @)QA<-]MI7;'21*8?%WG%P=]:,CL?UYX9%9]V@2\A4(N9=7 MH*MV)_;=P,@D.R4OI8$S=W:YX0Q6KGT OE]):0X#>_#.?S?I_P]02P,$% M @ SF-5Y^@&_"Q @ X@P T !X;"]S='EL97,N>&ULW5=M:]LP$/XK M0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZ MNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y M*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB6 M2;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9 M,&FM5X64,\$E#89BW3#GN-5W7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8 MDMLYS8).IF(M>05TK*B/\.M,DP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J* MW5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/ M[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*P MG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0ERHY M_U=3_ 102P,$% @ SF-5Y>*NQS $P( L !?3T\ M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5* M(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$ MWHI"/J:Q8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B M]#V,YU#BG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9J MZJ8IGJ,.>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48 MY0]02P,$% @ SF-5R0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J M%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I M2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC M":[?#'!X=/X!4$L#!!0 ( ,YC5=ED'F2&0$ ,\# 3 6T-O;G1E M;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=: MTMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E) M_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I* M&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7H MK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC* M30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( M ,YC5=6PF:$C 0 $,1 8 " @0P( !X;"]W;W)K&PO7 MBKL

JQ"(6,P$ "(" / " 9,0 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " #.8U7)!Z;HJT #X 0 &@ M @ 'S$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #.8U799!YDAD! #/ P $P @ '8$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" B% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://blackdiamondtherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bdtx-20231213.xsd bdtx-20231213_lab.xml bdtx-20231213_pre.xml tm2332757d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2332757d1_8k.htm": { "nsprefix": "BDTX", "nsuri": "http://blackdiamondtherapeutics.com/20231213", "dts": { "schema": { "local": [ "bdtx-20231213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "bdtx-20231213_lab.xml" ] }, "presentationLink": { "local": [ "bdtx-20231213_pre.xml" ] }, "inline": { "local": [ "tm2332757d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://blackdiamondtherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332757d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332757d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://blackdiamondtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-125566-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-125566-xbrl.zip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end